All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Symposium | Early intervention and use of ECP combinations in cGvHD
Featured
Video series
GvHD Hub EBMT Symposium 2024: 30 years of ECP in GvHD: Recommendations for the treatment of cGvHD
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
On April 14, 2024, the GvHD Hub held a symposium at the 50th European Society for Bone and Marrow Transplantation (EBMT) Annual Meeting on the role of extracorporeal photopheresis (ECP) in the management of chronic graft-versus-host disease (cGvHD).
Here, we share the presentation by Florent Malard, Hôpital Saint-Antoine and Sorbonne Université, Paris, FR, that explored early intervention and ECP-based combinations. Mallard covered use of ECP first-line, as well as ECP combinations in patients with steroid-refractory and steroid-dependent cGvHD, including recent approvals and findings from clinical trials.
Listen to this presentation as a podcast here:
Symposium | Early intervention and use of ECP combinations in cGvHD
Q&A session
This symposium closed with a panel Q&A session with live audience participation, where our panelists shared their thoughts on how ECP can affect lymphocyte count during and after treatment.
Symposium | Q&A | How ECP can affect lymphocyte count during and after treatment?
This independent educational activity was supported by Mallinckrodt Pharmaceuticals. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity.
- Flower MED, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008;112(7):2667-74. DOI: 10.1182/blood-2008-03-141481
- Jagasia M, Alyea EP, Ahmed S, et al. Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib: Early Safety Results of a Multicenter Study. Biol Blood Marrow Transplant. 2019;25(3):(Suppl_28-29). DOI: https://doi.org/10.1016/j.bbmt.2018.12.819
Video series
GvHD Hub EBMT Symposium 2024: 30 years of ECP in GvHD: Recommendations for the treatment of cGvHD
Your opinion matters
4 votes - 50 days left ...
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox